Comment on “Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data”.

HOME
>
論文・技術情報
>
Comment on “Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data”.

アブストラクト
ジャーナル名	World journal of urology
Pubmed追加日	2026/7/24
投稿者	Fan, Zhipeng; Li, Lei
組織名	Department of Oncology, Wuhan Asia General Hospital, Wuhan University of Science;and Technology, 300 Taizihu North Road, Wuhan, 430056, Hubei, China.;lilei1@wagh.com.cn.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/42496711/